<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1472</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2022-18-1-156-163</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>TOPICAL PROBLEM</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНАЯ ТЕМА</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Malignant neoplasms of the skin in recipients after kidney transplant: is the cancellation of immunosuppressive therapy inevitable?</article-title><trans-title-group xml:lang="ru"><trans-title>Злокачественные новообразования кожи у реципиентов ренальных трансплантатов: неизбежна ли отмена иммуносупрессии?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4415-0903</contrib-id><name-alternatives><name xml:lang="en"><surname>Perlin</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Перлин</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Dmitriy V. Perlin</bold></p><p><italic>86 im. Generala Karbysheva St., Volzhskiy 404120</italic></p></bio><bio xml:lang="ru"><p><bold>Дмитрий Владиславович Перлин </bold></p><p><italic>404120 Волжский, ул. им. генерала Карбышева, 86</italic></p></bio><email>dvperlin@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8807-8819</contrib-id><name-alternatives><name xml:lang="en"><surname>Shmanev</surname><given-names>A. O.</given-names></name><name xml:lang="ru"><surname>Шманев</surname><given-names>А. О.</given-names></name></name-alternatives><bio xml:lang="en"><p><italic>86 im. Generala Karbysheva St., Volzhskiy 404120</italic></p></bio><bio xml:lang="ru"><p><italic>404120 Волжский, ул. им. генерала Карбышева, 86</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0629-1270</contrib-id><name-alternatives><name xml:lang="en"><surname>Perlina</surname><given-names>A. D.</given-names></name><name xml:lang="ru"><surname>Перлина</surname><given-names>А. Д.</given-names></name></name-alternatives><bio xml:lang="en"><p><italic>Build. 1, 61/2 Shchepkina St., Moscow 129110</italic></p></bio><bio xml:lang="ru"><p><italic>129110 Москва, ул. Щепкина 61/2, корп. 1 </italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4711-9837</contrib-id><name-alternatives><name xml:lang="en"><surname>Terentiev</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Терентьев</surname><given-names>А. В.</given-names></name></name-alternatives><bio xml:lang="en"><p><italic>86 im. Generala Karbysheva St., Volzhskiy 404120</italic></p></bio><bio xml:lang="ru"><p><bold>Алексей Вячеславович Терентьев</bold></p><p><italic>404120 Волжский, ул. им. генерала Карбышева, 86</italic></p></bio><email>terentyevalex1988@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1388-4242</contrib-id><name-alternatives><name xml:lang="en"><surname>Kulikov</surname><given-names>P. A.</given-names></name><name xml:lang="ru"><surname>Куликов</surname><given-names>П. А.</given-names></name></name-alternatives><bio xml:lang="en"><p><italic>86 im. Generala Karbysheva St., Volzhskiy 404120</italic></p></bio><bio xml:lang="ru"><p><italic>404120 Волжский, ул. им. генерала Карбышева, 86</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Volgograd Regional Uronephrology Center</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Волгоградский областной уронефрологический центр»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">M.F. Vladimirsky Moscow Regional Research Clinical Istitute</institution></aff><aff><institution xml:lang="ru">ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-05-09" publication-format="electronic"><day>09</day><month>05</month><year>2022</year></pub-date><volume>18</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>156</fpage><lpage>163</lpage><history><date date-type="received" iso-8601-date="2021-08-07"><day>07</day><month>08</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-13"><day>13</day><month>10</month><year>2021</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1472">https://oncourology.abvpress.ru/oncur/article/view/1472</self-uri><abstract xml:lang="en"><p><bold>Background</bold>. With a constant increase in the number of renal transplant recipients and an increase in their life expectancy, the number of complications associated with immunosuppressive therapy is progressively increasing. The incidences of oncological diseases are approximately 100 times higher than the incidence in the general population. Skin neoplasms constitute a significant part of oncological diseases after kidney transplantation.</p><p><bold>Materials and methods</bold>. In our clinic in the period from 2010 to 2017, four patients with malignant neoplasms of the skin were observed. Three of them developed Kaposi’s sarcoma in the period from 6 months to 6 years after kidney transplantation, one was diagnosed with squamous cell skin cancer 10 years after the operation.</p><p><bold>Results</bold>. After histological verification, excision of neoplasms was performed in two cases, followed by a decrease in the dosage of immunosuppressive drugs; in one case, a complete conversion of immunosuppressive therapy was performed. During therapy, stabilization of the condition was noted, however, further deterioration in the function of the graft was noted, which led to the loss of kidney function and removal of the grafts. A patient with basal cell skin cancer underwent surgical treatment with a course X-ray radiation, but further progression led to the death of the patient.</p><p><bold>Conclusion</bold>. Kidney transplant patients are at high risk of developing skin malignancies and death from cancer. Early detection of the disease and complete withdrawal of immunosuppressive drugs – calcineurin inhibitors, despite the high probability of loss of graft function are still often remain necessary conditions for the treatment of patients with skin malignant neoplasms.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. С постоянным увеличением числа реципиентов ренальных трансплантатов и продолжительности их жизни прогрессивно растет количество осложнений, связанных с иммуносупрессивной терапией. Среди них по мере увеличения ее продолжительности все большую долю занимают онкологические заболевания. Частота встречаемости последних примерно в 100 раз превышает заболеваемость в общей популяции. Существенную часть онкологических заболеваний после пересадки почки составляют новообразования кожи.</p><p><bold>Материалы и методы</bold>. В клинике Волгоградского областного уронефрологического центра в период с 2010 по 2017 г. под наблюдением находились 4 пациента со злокачественными новообразованиями кожи. У 3 из них в период от 6 мес до 6 лет после трансплантации почки развилась саркома Капоши, у 1 больного диагностирован плоскоклеточный рак кожи через 10 лет после операции.</p><p><bold>Результаты</bold>. После гистологической верификации в 2 случаях было выполнено иссечение новообразований с последующим снижением дозы иммуносупрессивных препаратов, в 1 случае – полная конверсия иммуносупрессивной терапии. На фоне терапии наблюдалась стабилизация состояния, однако в дальнейшем отмечалось ухудшение функции трансплантата, которое привело к потере функции почки и удалению трансплантатов. Пациенту с базальноклеточным раком кожи было проведено хирургическое лечение с курсом близкофокусной лучевой терапии, однако дальнейшее прогрессирование привело к смерти пациента.</p><p><bold>Заключение</bold>. Пациенты после пересадки почки представляют собой группу высокого риска развития злокачественных образований кожи и смерти от онкологических заболеваний. Раннее выявление заболевания и полная отмена иммуносупрессивных препаратов – ингибиторов кальциневрина, несмотря на высокую вероятность потери функции трансплантата, все еще зачастую остаются необходимыми условиями лечения пациентов со злокачественными новообразованиями кожи.</p><p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>kidney transplantation</kwd><kwd>Kaposi’s sarcoma</kwd><kwd>squamous cell carcinoma</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>трансплантация почки</kwd><kwd>саркома Капоши</kwd><kwd>плоскоклеточный рак кожи</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Penn I Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1994;99–109.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Gupta A.K., Cardella C.J., Haberman H.F. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 1986;122(11):1288–93. DOI: 10.1001/archderm.1986.01660230080015.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Penn I. Cancers in cyclosporine-treated vs azathioprine-treated patients. Transplant Proc 1996;28(2):876–78.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>London N.J., Farmery S.M., Will E.J. et al. Risk of neoplasia in renal transplant patients. Lancet 1995;346(8972):403–6. DOI: 10.1016/s0140-6736(95)92780-8.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Montaner S., Sodhi A., Molinolo A. et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003;3(1):23–36. DOI: 10.1016/s1535-6108(02)00237-4.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Stallone G., Schena A., Infante B. et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005;352(13):1317–23. DOI: 10.1056/NEJMoa042831.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Campistol J.M., Gutierrez-Dalmau A., Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation 2004;77(5):760–2. DOI: 10.1097/01.tp.0000115344.18025.0b.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Peters T., Traboulsi D., Tibbles L.A., Mydlarski P.R. Sirolimus: a therapeutic advance for dermatologic disease. Skin Therapy Lett 2014;19(4):1–4.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Descoeudres B., Giannini O., Graf T. et al. No effect of sirolimus for Kaposi sarcoma in a renal transplant recipient. Transplantation 2006;81(10):1472–4. DOI: 10.1097/01.tp.0000203322.99037.d2.</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Alexandrov I., Molochkov V., Perlina A. et al. Everolimus for Kaposi’s sarcoma treatment after kidney transplantation. Vestnik transplantologii i iskusstvennykh organov = Russian Journal of Transplantology and Artificial Organs 2015;17(2):60–3. (In Russ.). DOI: 10.15825/1995-1191-2015-2-60-63.</mixed-citation><mixed-citation xml:lang="ru">Александров И.В., Молочков В.А., Перлина А.Д. и др. Применение эверолимуса при лечении саркомы Капоши после трансплантации почки. Вестник трансплантологии и искусственных органов 2015;17(2):60–3. DOI: 10.15825/1995-1191-2015-2-60-63.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><mixed-citation>Van den Akker J.M., Wetzels J.F., Hoitsma A.J. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006;70(7):1355–7. DOI: 10.1038/sj.ki.5001792.</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Malignant tumors in Russia in 2014 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2016. 250 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2016. 250 с.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Hartevelt M.M., Bavinck J.N., Kootte A.M. et al. Incidence of skin cancer after renal transplantation in Netherlands. Transplantation 1990;49(3):506–9. DOI: 10.1097/00007890-199003000-00006.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Sheil A.G., Disney A.P., Mathew T.G. et al. Malignancy following renal transplantation. Transplant Proc 1992;24(5):1946–7.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bavinck J.N., De Boer A., Vermeer B.J. et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993;129(3):242–9. DOI: 10.1111/j.1365-2133.1993.tb11841.x.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Penn I. Skin disorders in organ transplant recipients. External anogenital lesions. Arch Dermatol 1997;133(2):221–3.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Marks R., Jolley D., Lectsas S., Foley P. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med J Aust 1990;152(2):62–6. DOI: 10.5694/j.1326-5377.1990.tb124456.x.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Dyall-Smith D., Ross J.B. Cutaneous malignancies in renal transplant recipients from Nova Scotia, Canada. Australas J Dermatol 1995;36(2):79–82. DOI: 10.1111/j.1440-0960.1995.tb00937.x.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Gruber S.A., Gillingham K., Sothern R.B. et al. De novo cancer in cyclosporinetreated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplant 1994;8(4):388–95.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>LiddingtonM., RichardsonA.J., Higgins R.M. et al. Skin cancer in renal transplant recipients. Br J Surg 1989;76(10):1002–5. DOI: 10.1002/bjs.1800761005.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Euvrard S., Kanitakis J., Pouteil-Noble C. et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995;33(2 Pt 1):222–9. DOI: 10.1016/0190-9622(95)90239-2.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Naldi L., Fortina A.B., Lovati S. et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registrybased study. Transplantation 2000;70(10): 1479–84. DOI: 10.1097/00007890200011270-00015.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Ramsay H.M., Fryer A.A., Reece S. et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000;36(1):167–76. DOI: 10.1053/ajkd.2000.8290.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Barrett W.L., First M.R., Aron B.S., Penn I. Clinical course of malignancies in renal transplant recipients. Cancer 1993;72(7):2186–9. DOI: 10.1002/10970142(19931001)72:7&lt;2186::aidcncr2820720720&gt;3.0.co;2-2.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Euvrard S., Chardonnet Y., Pouteil-Noble C. et al. Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplantrecipients. Cancer 1993;72(7):2198–206. DOI: 10.1002/1097-0142(19931001)72:7&lt;2198::aid-cncr2820720722&gt;3.0.co;2-q.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Moloney F.J., Comber H., O’Lorcain P. et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006;154(3):498–504. DOI: 10.1111/j.1365-2133.2005.07021.x.</mixed-citation></ref></ref-list></back></article>
